Objective To investigate whether rituximab, an anti–B cell therapy, improves symptoms of
fatigue and oral dryness in patients with primary Sjögren's syndrome (SS). Methods We …

Objective: Primary Sjögren syndrome (pSS) causes significant systemic symptoms including
fatigue as well as glandular dysfunction. There are currently no effective systemic therapies; …

Objective. To study the efficacy and safety of B cell depletion with rituximab, a chimeric
murine/human anti-CD20 monoclonal antibody, in patients with primary Sjögren's syndrome …

Objective The Sjögren's Syndrome Foundation clinical practice guidelines (CPGs) are
designed to improve quality and consistency of care in Sjögren's syndrome by offering …

Background: Primary Sjögren syndrome (pSS) is an autoimmune disorder characterized by
ocular and oral dryness or systemic manifestations. Objective: To evaluate efficacy and …

Objective To identify the principal determinants of health‐related quality of life (HRQOL)
impairment in patients with active primary Sjögren's syndrome (SS) participating in a large …

Objective To study the safety and clinical efficacy of rituximab therapy for primary Sjögren's
syndrome, as well as to investigate its mechanisms. Methods Patients with primary Sjögren's …

Abstract Introduction Primary Sjögren's syndrome (pSS) is an autoimmune disorder affecting
exocrine glands; however, a subgroup of pSS patients experience systemic extra-glandular …

Objectives To evaluate the efficacy and safety of rituximab in patients with primary Sjögren's
syndrome (pSS). Methods The AutoImmune and Rituximab registry has included 86 patients …

Objective To evaluate changes in salivary gland echostructure and vascularization after
rituximab treatment in patients with primary Sjögren's syndrome (SS). Methods Twenty‐eight …